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The knowledge of metabolic profile of synthetic cannabinoids is important for the detection 
of the drugs in urinalysis due to the typical absence or low abundance of parent cannabinoids 
in human urine. The fungus Cunninghamella elegans has been reported to be a useful tool for 
metabolism study and thus applicability to synthetic cannabinoids metabolism was examined. 
In this study, 8-quinolinyl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22), 8-
quinolinyl 1-pentyl-1H-indole-3-carboxylate (PB-22), [1-(5-fluoropentyl)-1H-indol-3-
yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR-11) and (1-pentyl-1H-indol-3-
yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) were incubated with 
Cunninghamella elegans and the metabolites were identified using liquid chromatography-
quadrupole time-of-flight mass spectrometry. The obtained metabolites were compared with 
reported human metabolites to assess the suitability of the fungus to extrapolate human 
metabolism. 5F-PB-22 underwent, dihydroxylation, dihydrodiol formation, oxidative 
defluorination, oxidative defluorination to carboxylic acid, ester hydrolysis and glucosidation, 
alone and/or in combination. The metabolites of PB-22 were generated by hydroxylation, 
dihydroxylation, trihydroxylation, dihydrodiol formation, ketone formation, carboxylation, 
ester hydrolysis and glucosidation, alone and/or in combination. XLR-11 was transformed 
through hydroxylation, dihydroxylation, aldehyde formation, carboxylation, oxidative 
defluorination, oxidative defluorination to carboxylic acid and glucosidation, alone and/or in 
combination. UR-144 was metabolised by hydroxylation, dihydroxylation, trihydroxylation, 
aldehyde formation, ketone formation, carboxylation, N-dealkylation and combinations. 
These findings were consistent with previously reported human metabolism except for the 
small extent of ester hydrolysis observed and absence of glucuronidation. Despite the 
limitations, Cunninghamella elegans demonstrated the capacity to produce a wide variety of 
metabolites including some major human metabolites of XLR-11 and UR-144 at high 
abundance, showing the potential for metabolism of newly emerging synthetic cannabinoids. 
 















CB1 Cannabinoid type 1 
CB2 Cannabinoid type 2 
C. elegans Cunninghamella elegans 
ESI Electrospray ionization source 
5F-PB-22 8-quinolinyl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate  
5F-PI-COOH 5-fluoropentylindole-3-carboxylic acid 
HLM Human liver microsomes 
LC-QqQ Liquid chromatography-triple quadrupole 
LC-QTOF-MS Liquid chromatography-quadrupole time-of-flight 
mass spectrometry 
MS Mass spectrometry 
NMR Nuclear magnetic resonance 
PB-22 8-quinolinyl 1-pentyl-1H-indole-3-carboxylate 



























New psychoactive substances have been increasingly appearing on the drug market. In 
particular, synthetic cannabinoids are the major class of drugs and over 160 compounds have 
been detected since 2008 with 24 of them appearing for the first time in 2015 [1]. Synthetic 
cannabinoids are cannabinoid type 1 (CB1) and type 2 (CB2) receptor agonists like Δ
9-
tetrahydrocannabinol, the active ingredient of cannabis, producing psychoactive effects but 
can be significantly more potent since cannabinoids and metabolites often have higher 
affinity and full agonist activity for both CB1 and CB2 receptor [2, 3]. As such, adverse health 
effects including seizures, psychosis, hallucinations, cardiotoxic effects, coma and deaths 
have been associated with the use of synthetic cannabinoids and it has become a serious 
public health concern [4]. 
Due to the emergence of many synthetic cannabinoids within a short period, understanding of 
their pharmacology including metabolism is still limited. Knowledge of metabolites is 
important for forensic and clinical cases to prove the consumption of particular cannabinoids 
in urinalysis because synthetic cannabinoids are generally extensively metabolised and are 
usually not found without modification or found in low abundance in urine, requiring 
abundant and specific metabolites to be targeted instead [5-14]. 
Different approaches have been taken for metabolite identification studies. While providing 
the most reliable data [15], self-administration of drugs is difficult due to possible side effects 
and ethical concerns and therefore other approaches are commonly taken such as in vitro 
human hepatocytes [7-9, 16-20] and human liver microsomes (HLM) [6, 14, 21-26], and in 
vivo animals [5, 25-27]. The combination of controlled experiments such as human 
hepatocytes and authentic human urine analysis particularly appears to be valuable [28, 29]. 
However, cost, maintenance, species differences and/or ethics can be an issue with these 
models [30]. Furthermore, quantity of metabolites obtained is usually not sufficient for 
isolation [30], limiting the analysis to the use of mass spectrometry. However, unambiguous 
structural elucidation may not be possible without techniques such as nuclear magnetic 
resonance (NMR) spectroscopy [29]. 
While less common, the potential of microbial models for metabolic studies have been 
investigated over the past few decades [30]. Cunninghamella elegans (C. elegans) is a fungus 
species known to metabolise many xenobiotics regio- and stereo-selectively, similar to 
mammalian metabolism [30]. The fungus has enzymatic activity for both phase I and II 
enzymes [31] and possesses cytochrome P450 enzymes known as CYP509A1, which are 
close to CYP51 family [32]. While little is known about the activity of CYP509A1, the 
fungus is capable of various reactions, such as hydroxylation, carboxylation, dihydrodiol 
formation, oxidative defluorination, N-dealkylation, glucosidation and sulfation [30, 33], 
including those catalysed by human CYP1A2, CYP2C9, CYP2C19 and CYP2D6 [2, 33-37]. 
CYP3A4 is reported to be the major enzyme involved in the metabolism of [1-(5-
fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR-11) and (1-
pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144), two of the drugs 
investigated in this study, while CYP1A2 has a minor influence. There is no literature on 
specific enzymes responsible for the metabolism of 8-quinolinyl 1-(5-fluoropentyl)-1H-
indole-3-carboxylate (5F-PB-22) and 8-quinolinyl 1-pentyl-1H-indole-3-carboxylate (PB-22), 
the other two drugs investigated.  Some of the advantages of C. elegans include low cost, no 
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ethical concern involved, simple and cheap maintenance of stock fungal cultures that can be 
subcultured, high reproducibility, diverse metabolic profile and larger amounts of metabolite 
produced, which might result in more fragment ions in mass spectrometric analysis, 
facilitating structural elucidation [30, 38]. More importantly, production of large amounts of 
metabolites have allowed for the structural characterisation of metabolites by NMR 
spectroscopy [39, 40]. Therefore, C. elegans may prove useful for synthetic cannabinoids 
metabolism study, especially where reference standards for metabolites of new compounds 
are not available.  
The purpose of the study was to identify the metabolites of 5F-PB-22, PB-22, XLR-11 and 
UR-144 by C. elegans and to compare the fungal metabolites with human in vivo and in vitro 
metabolites reported in literature to examine whether C. elegans might have the possibility to 
be used as a complementary model for metabolism studies of synthetic cannabinoids with 
production of appropriate human metabolites. We have previously investigated the 
metabolism of synthetic cannabinoids JWH-018, JWH-073 and AM2201 by C. elegans and 
their metabolic profiles were in good agreement with human metabolism, producing majority 
of the phase I human metabolites [33, 41]. The four synthetic cannabinoids were chosen 
because they have different structural classes from the cannabinoids in our previous study 
and human in vivo and/or in vitro metabolism data are available. Metabolites were analysed 
by liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) with 
the aid of liquid chromatography-triple quadrupole (LC-QqQ) mass spectrometry. LC-QTOF-
MS was mainly employed because it provides high-resolution mass spectrometric data, 
increasing the confidence of characterisation of metabolites by distinguishing isobaric 
compounds. 
 
Materials and Methods 
Chemicals and reagents 
5F-PB-22 and PB-22 were obtained from PM separations (Capalaba, QLD, Australia) and 
XLR-11 and UR-144 were from the National Measurement Institute (North Ryde, NSW, 
Australia). Reagent grade dichloromethane, LC grade acetonitrile, acetone and sodium 
chloride were obtained from Chemsupply (Gilman, SA, Australia). LC-MS grade formic acid 
was obtained from Sigma–Aldrich (St. Louis, MO, USA). Glycerol and potassium 
dihydrogen orthophosphate were from Ajax Chemicals (Auburn, NSW, Australia). Potato 
dextrose agar, glucose, peptone, and yeast extract were purchased from Oxoid Australia 
(Adelaide, SA, Australia). 
 
Biotransformation by fungus and sample preparation 
C. elegans ATCC 10028b (Cryosite Ltd., South Granville, NSW, Australia) was cultured on 
potato dextrose agar plates at 27 °C for 5 days ensuring the whole plates were covered with 
mycelia. The mycelia were then transferred to sterile physiological saline solution (1 plate of 
mycelia per 5 mL) and homogenized for 5 min. Approximately 1.5 mL aliquots of the 
homogenate were inoculated into 100 mL growth media, prepared according to the methods 
in [42], in 250 mL Erlenmeyer flasks. The cultures were incubated for 48 h at 26 °C and 180 
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rpm on an Infors HT Multitron rotary shaker (In vitro Technologies, Noble Park North, VIC, 
Australia). After 48 h, 0.5 mL of 5F-PB-22, PB-22, XLR-11 or UR-144 in acetone (2 
mg/mL) was added to the culture and incubated for further 72 h. Two control samples were 
also incubated and consisted of 1) media and fungus without drugs to determine compounds 
unrelated to the drugs and 2) media and drug without fungus.to determine degradation of the 
drugs. 
After 72 h, fungus was removed by filtration using Buchner funnel and the remaining 
solution was extracted with dichloromethane (3 × 50 mL). The extracts were combined and 
evaporated to dryness using a Buchi rotary evaporator (In vitro Technologies, Noble Park 
North, VIC, Australia) followed by a vacuum pump. Each samples was reconstituted in 2 mL 
acetonitrile and was further diluted in acetonitrile by 10-fold before injecting to LC-MS. 
 
LC-QTOF analysis 
Chromatographic separation of samples was performed using an Agilent 1290 LC system 
with an Agilent Zorbax Eclipse XDBC18 analytical column (150 mm × 4.6 mm, 5 µm). 
Mobile phases were 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B) at 
a flow rate of 0.4 mL/min. Due to the difference in polarity of the cannabinoids, two mobile 
phase gradients were used. For 5F-PB-22 and PB-22, 30% B was held until 1 min, ramped to 
50% B at 3 min, 90% B at 20 min and held until 24 min, then ramped down to 30% B at 25 
min and held for re-equilibration until 30 min. For XLR-11 and UR-144, 30% B was held 
until 1 min, ramped to 60% B at 3 min, to 90% B at 20 min and held until 24 min, and 
ramped down to 30% B at 25 min for re-equilibration until 30 min. Injection volume was 4 
µL (MS mode) and 10 µL (targeted MS/MS mode). 
Mass spectrometric data was acquired on an Agilent 6510 Accurate Mass Q-TOF Mass 
Spectrometer, equipped with an electrospray ionization source (ESI) source operated in 
positive ion mode. The following parameters were used: scanning mass range, m/z 100–1000 
(MS), m/z 100–950 (MS/MS); capillary voltage, 3500 V; nebulizer pressure, 30 psig; gas 
flow, 5 L/min; gas temperature, 325 °C; fragmentor voltage, 160 V (XLR-11, UR-144), 80 V 
(5F-PB-22, PB-22); collision energy, 10, 20 and 40 eV; skimmer voltage, 65 V. Mass 
calibration was performed over the m/z 50–3200 range with the mixture provided by the 
manufacturer. Automated real-time calibration during runs was in place using the following 
reference masses: m/z 121.0509 and m/z 922.0098. 
Chromatographic and mass spectrometric data was analysed using Agilent MassHunter 
Workstation Software Qualitative Analysis (version B.06.00) for MS scan both manually 
looking at peaks present in fungus samples but absent in controls and with a PCDL library 
created by Agilent MassHunter PCDL Manager (version B.04.00) with known metabolites of 
the drugs to search for the potential metabolites. MS/MS scans were performed on the 
precursor ions which were suspected to be metabolites. Search parameters were as follows: 
mass tolerance, 20 ppm; maximum number of matches, 8; absolute peak area ≥ 5000. The 
criteria for metabolites were as follows: mass error of the protonated ion ≤ 5.1 ppm; 
consistent fragmentation pattern with proposed structure; reasonable retention time relative to 





An Agilent 6490 Triple Quadrupole mass spectrometer with ESI source (positive ion mode) 
coupled with an Agilent 1290 LC system was used for product ion scans for a few PB-22 
metabolites (m/z 405 and 409) where some fragment ions for the potential metabolites were 
absent in QTOF analysis. Data derived from QqQ analysis is indicated in Supplementary 
Table II. All the chromatographic conditions and column used were the same as for QTOF 
analysis except for the injection volume of 2 µL. The following mass spectrometric 
conditions were used: scanning mass range, m/z 85–500; fragmentor voltage, 380 V; collision 





5F-PB-22 metabolites found after fungus incubation are listed in Supplementary Table I 
including proposed biotransformation, retention time, elemental composition, exact mass, 
accurate mass, mass error, and diagnostic product ions. Similarly, PB-22, XLR-11, and UR-
144 metabolites are listed in Supplementary Tables II, III, and IV, respectively. Fig. 1 
shows MS/MS spectra as well as their structures with suggested fragmentation patterns of 5F-
PB-22, PB-22, XLR-11 and UR-144 and their major metabolites. 
 
5F-PB-22 
Sixteen metabolites (labelled as F1 – F16 in the order of retention time) were detected after 
incubation with C. elegans. They eluted between 6.4 min and 12.6 min before the parent drug 
at 17.6 min (Fig. 2a). The metabolites were generated by dihydrodiol formation (F10) 
followed by hydroxylation (F3), dihydroxylation (F7-F9), hydroxylation (F14-F16), oxidative 
defluorination to carboxylic acid (F13) followed by hydroxylation (F5, F6, F11), oxidative 
defluorination with dihydrodiol (F1), ester hydrolysis resulting in 5-fluoropentylindole-3-
carboxylic acid (5F-PI-COOH, F12) followed by glucosidation (F2) or hydroxylation (F4). 
The mass errors of the metabolites based on the proposed biotransformations were all within 
1.39 ppm. The top three abundant metabolites based on peak area were dihydrodiol (F10), 
hydroxylation (F15) and oxidative defluorination to carboxylic acid (F13).  Proposed 
metabolic pathway of 5F-PB-22 is shown in Fig. 3. Comparison of the fungal metabolites in 
this study with human hepatocytes and HLM metabolites in the literature is shown in Table I.  
 
PB-22 
A total of 30 metabolites (P1-P30) were found to elute between 6.2 min and 15.1 min all 
before the parent drug at 21.7 min (Fig. 2b). The following biotransformation was observed: 
carboxylation (P24) followed by hydroxylation (P12), dihydrodiol formation (P27) followed 
by hydroxylation (P3, P7) or ketone formation (P8, P14), dihydroxylation (P13, P15, P16, 
P19), hydroxylation (P26, P28), ketone formation (P29, P30) followed by hydroxylation (P17, 
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P20-P23, P25) and glucosidation (P1) or dihydroxylation (P4, P5, P9, P18), trihydroxylation 
(P2), ester hydrolysis leading to pentylindole-3-carboxylic acid (PI-COOH) followed by 
hydroxylation (P6, P11) or glucosidation (P10). The mass errors of all the metabolites were 
2.51 ppm or less. Three major fungal metabolites were dihydroxylation (P13), dihydrodiol 
formation with ketone formation (P8) and dihydroxylation (P16). Proposed metabolic 
pathway of PB-22 is shown in Fig. 4. Comparison of the fungal metabolites in this study with 
human hepatocytes and HLM metabolites in the literature is shown in Table II. 
 
XLR-11 
Twenty six metabolites (X1-X26) were observed between 7.6 min and 14.6 min with the 
parent drug eluting at 20.9 min (Fig. 2c). XLR-11 was found to undergo aldehyde formation 
(X26), carboxylation (X22) followed by glucosidation (X14, X18) or hydroxylation (X10), 
hydroxylation (X21, X23), dihydroxylation (X3, X6, X9, X11-X13, X19, X20), oxidative 
defluorination (X25) followed by aldehyde formation (X16) or carboxylation (X8) or 
hydroxylation (X2, X7), oxidative defluorination to carboxylic acid (X24) followed by 
aldehyde formation (X15, X17) or carboxylation (X5) or hydroxylation (X1, X4). The mass 
errors of all the metabolites were within 5.10 ppm. Three most abundant metabolites were 
hydroxylation (X21), carboxylation (X22) and hydroxylation (X23). Proposed metabolic 
pathway of XLR-11 is shown in Fig. 5. The fungal metabolites in this study are compared 
with the metabolites in human urine, human hair, human hepatocytes, HLM and HepaRG 
cells that have been reported in the literature (Table III). 
 
UR-144 
Twenty five metabolites (U1-U25) were detected, eluting between 6.2 min and 17.4 min 
before the parent drug at 26.1 min (Fig. 2d). The biotransformation included aldehyde 
formation followed by hydroxylation (U19) or ketone formation (U21), carboxylation 
followed by hydroxylation (U6, U8, U10, U12, U15), dihydroxylation (U7, U11, U13, U16), 
hydroxylation (U22-U25), ketone formation followed by carboxylation (U17, U20) or 
hydroxylation (U14, U18), N-dealkylation followed by hydroxylation (U4, U9), 
trihydroxylation (U1-U3, U5). The mass errors of the proposed metabolites were all within 
2.04 ppm. Top three abundant metabolites were dihydroxylation (U7), dihydroxylation (U11) 
and carboxylation with hydroxylation (U10). Proposed metabolic pathway of XLR-11 is 
shown in Fig. 6. The observed fungal metabolites are compared with the metabolites in 











In MS/MS scan, 5F-PB-22 was fragmented to the ions at m/z 144 (an unchanged indole 
moiety) and 232 (an unaltered 5-fluoropentylindole moiety) and they were used as the basis 
for determining the structures of the metabolites (Fig. 1). All three hydroxy metabolites (m/z 
393, F14-F16) were found to be hydroxylated at the fluoropentyl side chain indicated by the 
fragment ions at m/z 144 representing an unchanged indole ring and at m/z 248 representative 
of a hydroxylated fluoropentylindole moiety. Two dihydroxy metabolites (m/z 409, F7, F8) 
showed fragment ions at m/z 144 and 248 indicating hydroxylation once at the fluoropentyl 
side chain and another at the quinoline moiety. F9 was another dihydroxy metabolite, 
hydroxylated twice at the fluoropentylindole moiety as shown by the fragment ion at m/z 264. 
But the lack of fragment ions corresponding to the indole moiety limited further 
determination as to whether hydroxylation took place at the fluoropentyl side chain, the 
indole moiety or at both. A metabolite with dihydrodiol formation (m/z 411, F10) was 
characterised by the fragment ions at m/z 144 and 232 (Fig. 1), suggesting dihydrodiol 
formation at the quinoline moiety. Further hydroxylation of F10 led to the metabolite (m/z 
427, F3) with a hydroxy group at the fluoropentylindole moiety as indicated by the fragment 
ion at m/z 248. 
Oxidative defluorination to carboxylic acid (m/z 389, F13) was suggested by the fragment 
ions at m/z 144 (an unaltered indole ring) and 244 (a carboxylated pentylindole moiety). 
These fragments themselves only indicate that 5F-PB-22 was defluorinated and that the 
pentyl side chain has two additional oxygen atoms and two less hydrogen atoms. However, it 
is probably an N-pentanoic acid as it is reported to be a major metabolite of 5F-PB-22 in 
human hepatocytes studies by Wohlfarth et al. [17]. Also, oxidative defluorination to 
carboxylic acid is a biotransformation previously observed for a synthetic cannabinoid 
AM2201 by C. elegans [33]. Further hydroxylation of F13 resulted in F5, F6 and F11 (m/z 
405). F5 and F11 were hydroxylated at the quinoline moiety as the fragment ions at m/z 144 
and 244 were still present. F6 was hydroxylated at the indole moiety, indicated by the 
fragment ions at m/z 160 (a hydroxylated indole ring) and 260 (a hydroxylated and 
carboxylated pentylindole). Although oxidative defluorination by itself was not observed, a 
metabolite with oxidative defluorination and dihydrodiol formation was indicated (m/z 409, 
F1). The only fragment ion detected was at m/z 230 suggesting a quinoline moiety with 
dihydrodiol formation and a pentylindole moiety with a hydroxy group. Despite the lack of 
the m/z 144 fragment ion, the position of the hydroxy group can be considered to be at the 
terminal carbon of the pentyl side chain since oxidative defluorination is a commonly 
reported pathway to simultaneously defluorinate and hydroxylate fluorinated synthetic 
cannabinoids [2, 6, 7, 16, 18, 19] and it has been reported for C. elegans [33].  
Ester hydrolysis led to the 5F-PI-COOH metabolite (m/z 250, F12) as indicated by the 
fragment ions at m/z 118 and 232 suggesting an unchanged indole moiety and unmodified 5-
fluoropentylindole moiety, respectively. There was another unknown peak with m/z 250 in 
the extracted ion chromatogram, but careful examination of mass spectrum in full scan mode 
revealed the presence of a coeluting protonated ion at m/z 412, which has mass error of 1.39 
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ppm for a glucoside of F12. Thus, it seems to be a glucoside of 5F-PI-COOH with in-source 
fragmentation (m/z 412, F2). In-source fragmentation of acyl glucuronides is reported for 
synthetic cannabinoid metabolites including 5F-PB-22 [16, 17] and is likely to occur with 
glucosides. A metabolite resulting from hydroxylation of F12 was shown by the fragment 
ions at m/z 248 indicating a 5-fluorohydroxypentylindole moiety and 134 corresponding to a 
hydroxyindole moiety (m/z 266, F4). 
 
PB-22 
PB-22 was fragmented similarly to 5F-PB-22 and resulted in two product ions at m/z 144 and 
214 (Fig. 1), corresponding to an unchanged indole ring and an unaltered pentylindole moiety. 
Both hydroxy metabolites (m/z 375, P26, P28) underwent hydroxylation at the pentyl side 
chain as shown by the fragment ions at m/z 144 and 230 with the latter indicating a 
hydroxylated pentylindole moiety. A dihydroxy metabolite (m/z 391, P13) showed the 
fragment ions at m/z 144 and 230 (Fig. 1), indicating hydroxylation at both the pentyl side 
chain and the quinoline moiety while the other three dihydroxy metabolites (P15, P16, P19) 
were hydroxylated twice at the pentyl side chain as suggested by the fragment ions at m/z 144 
and 246. A trihydroxylated metabolite (m/z 407, P2) was indicated to have two hydroxy 
groups at the pentyl side chain and another at the quinoline moiety (m/z 144, 246). A 
metabolite with dihydrodiol formation at the quinoline moiety (m/z 393, P27) was suggested 
by the ions at m/z 144 and 214 representing an unchanged pentylindole moiety. 
Hydroxylation of P27 at the pentyl side chain resulted in (m/z 393, P3, P7) as indicated by the 
ions at m/z 144 and 230. The retention time and fragmentation pattern of P3 and F1 indicated 
they are identical, suggesting the position of hydroxylation at the terminal carbon. Notably, 
for P7 the fragment ion at m/z 230 was not observed likely because the ion suppression 
occurred due to the coeluting metabolite P8 (peaks at m/z 228 and 229 are seen in the MS/MS, 
data not shown). However, product ion scan by the LC-QqQ revealed a clear peak at m/z 230. 
Further oxidation of P3 and P7 appeared to form metabolites with a ketone group at the 
pentyl side chain with dihydrodiol at the quinoline moiety as evidenced by the fragment ions 
at m/z 144 and 228. 
Metabolites with a ketone group at the pentyl side chain (m/z 373, P29, P30) were 
characterised by the fragment ions at m/z 144 and 228, the latter indicating a pentylindole 
moiety with a ketone group. Further hydroxylation occurred at the quinoline moiety for P17, 
P20, P22 and P25 (m/z 389) indicated by the fragment ions at m/z 144 and 228 and at the 
pentyl side chain for P21 and P23 suggested by the fragment ions at m/z 144 and 244. A 
glucoside of a hydroxylated metabolite with ketone was detected   (m/z 551, P1) but it was 
not a glucoside of any of the phase I metabolites found as the position of the hydroxylation 
for this metabolite was at the indole moiety (m/z 160, 244). Four metabolites with a ketone 
group at the side chain and dihydroxylation (m/z 405, P4, P5, P9, P18) were formed. P4 has a 
hydroxy group each at the indole ring and the quinoline moiety (m/z 160, 244), P5 and P9 at 
the pentyl side chain and the quinoline moiety (m/z 144, 244) and P18 twice at the pentyl side 
chain (m/z 144, 260). For P9 and P18, the fragment ion at m/z 144 was absent but was 
confirmed by the LC-QqQ analysis. P24 (m/z 389) showed the fragment ions at m/z 144, 244 
and based on the retention time and fragmentation pattern it was considered to be identical to 
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F13 and is proposed to be an N-pentanoic acid metabolite. Also, P12 was determined to be 
identical to F5 and is proposed to be formed by hydroxylating P24 at the quinoline ring. 
Similarly to 5F-PB-22, a glucoside of PI-COOH formed from ester hydrolysis (m/z 394, P10) 
was largely fragmented to m/z 232 by in-source fragmentation. Several fragment ions 
including m/z 118 and 214 suggested an unchanged pentylindole moiety. PI-COOH with 
hydroxylation at the pentyl side chain (m/z 248, P6, P11) was represented by the fragment 
ions at m/z 130 (an unaltered indole) and 230.  
 
XLR-11 
The structure of XLR-11 is similar to 5F-PB-22 with the quinoline moiety replaced by the 
tetramethylcyclopropyl (TMCP) ring. As such, the fragmentation pattern of XLR-11 was 
similar; m/z 144, 232 and additionally 125 (Fig. 1), corresponding to the TMCP moiety were 
observed. Hydroxylated metabolites (m/z 346, X21, X23) were found to have a hydroxy 
group at the TMCP ring as indicated by the fragment ions at m/z 144 and 232 (Fig. 1). The 
absence of the fragment ion at m/z 125 also indicated the modification at the TMCP ring. 
There are three possible positions of hydroxylation: the alpha carbon to the carbonyl group, 
two methyl groups on the same side of the cyclopropyl ring as the hydrogen atom on the 
alpha carbon, which is an (E)-isomer, and two methyl groups on the other side of the ring 
from the hydrogen, a (Z)-isomer. Wohlfarth et al. reported, in their human hepatocytes 
studies, three hydroxy glucuronides with the two diastereomers eluting closely [16]. Thus, it 
is possible that the diastereomers might have coeluted under the chromatographic condition 
employed, resulting in two apparent peaks. Eight dihydroxy metabolites (m/z 362, X3, X6, 
X9, X11-X13, X19, and X20) were detected. X3, X9 and X11 were hydroxylated once each 
at the fluoropentyl side chain and at the TMCP ring (m/z 144, 248) and X6, X12, X13, X19 
and X20 twice at the TMCP ring (m/z 144, 232). Aldehyde formation at the TMCP ring (m/z 
344, X26) was characterised by the fragment ions at m/z 144 and 232. In fact, aldehydes are 
highly reactive and might undergo subsequent reaction before being detected. However, 
intermediate aldehyde metabolite of ebastine is reported to be isolated and characterised 
along with subsequent carboxylic acid metabolite after incubation with Cunninghamella 
blakesleeana, another species of the genus Cunninghamella [43], and therefore aldehyde is 
tentatively proposed in this study. 
 
Three metabolites (m/z 360, X14, X18, X22) were observed with the fragment ions at m/z 144 
and 232 corresponding to carboxylic acid at the TMCP ring. Similar to hydroxylation of the 
TMCP ring, there appears to be two possible positions for carboxylation at methyl carbons 
generating (E)- and (Z)-isomers. However, this does not explain the presence of three 
metabolites. Therefore, it is likely that one or two of the three metabolites are phase II 
metabolites with in-source fragmentation. As the retention time of X22 is relatively late 
compared to the other two, it is possible that X22 is a carboxy metabolite and X14 and X18 
are glucosides of carboxy metabolites. The reason for only one chromatographic peak for the 
carboxy metabolite may be explained by coelution whereas the phase II metabolites may 
have sufficient difference in property to be separated by chromatography under the condition 
employed. Wohlfarth et al. also reported the presence of single carboxy metabolite and it was 
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the peak eluting last among the metabolites with m/z 360 and their glucuronides [16]. 
Alternatively, X14 or X18 may be hemiacetal formation as reported by Wohlfarth et al. [16]. 
Carboxylation followed by hydroxylation (m/z 376, X10) showed the fragments at m/z 144 
and 248 indicating hydroxylation at the fluoropentyl side chain. 
A metabolite with oxidative defluorination (m/z 328, X25) was characterised by the fragment 
ions at m/z 125, 144 and 230 indicating a hydroxylated pentyl side chain. Hydroxylation of 
X25 led to X2 and X7 (m/z 344) with the fragment ions at m/z 144 and 230 suggesting 
hydroxylation at the TMCP ring. Further oxidation of X2 or X7 formed an aldehyde 
metabolite (m/z 342, X16) and a carboxylated metabolite (m/z 358, X8) both with the 
fragment ions at m/z 144 and 230. Oxidative defluorination to carboxylic acid (m/z 342, X24) 
was indicated by the fragment ions at m/z 125, 144 and 244. X24 was subsequently 
hydroxylated at the TMCP ring (m/z 358, X1, X4), further oxidated to aldehyde (m/z 356, 
X15, X17) and carboxylic acid (m/z 372, X5) all with the fragment ions at m/z 144 and 244. 
Notably, if the two metabolites at m/z 356 (X15 and X17) are aldehydes as tentatively 
assigned, it would be the only case where the (E)- and (Z)-isomers are not coeluted. 
Therefore, it is possible that one of them is a metabolite that underwent dihydroxylation 
followed by internal dehydration as previously reported [16]. 
 
UR-144 
UR-144 is a defluorinated analogue of XLR-11. Hence, it showed the same fragment ions at 
m/z 125, 144 and the defluorinated ion at m/z 214, instead of 232 (Fig. 1). Hydroxylation (m/z 
328) of UR-144 occurred at the pentyl side chain with the fragment ions at m/z 125, 144 and 
230 (U22, U23) and at the TMCP ring with the ions at 144 and 214 (U24, U25). U22 
matched well in retention time with X25 (oxidative defluorination metabolite of XLR-11), 
suggesting 5-hydroxypentyl metabolite. The position of hydroxylation for U23 cannot be 
determined but is likely to be 4-hydroxypentyl metabolite since (ω)-OH and (ω-1)-OH 
metabolites of alkyl side chain have been reported for some synthetic cannabinoids [33, 44]. 
Further hydroxylation of hydroxy metabolites resulted in dihydroxylation (m/z 344, U7, U11, 
U13, U16) with one hydroxy group at the pentyl side chain and another at the TMCP ring as 
indicated by the fragment ions at m/z 144 and 230 (Fig. 1). U7 and U11 agreed well with X2 
and X7, respectively, indicating that the hydroxy group at the side chain is likely to be at the 
terminal carbon. Trihydroxylated metabolites (m/z 360, U1-U3, U5) were then formed with a 
hydroxy group at the pentyl side chain and two at the TMCP ring as shown by the fragment 
ions at m/z 144 and 230. N-dealkylation of U24 and U25 resulted in despentyl hydroxy 
metabolites (m/z 258, U4, U9) with the fragment ion at m/z 144. 
Aldehyde formation at the TMCP ring followed by hydroxylation at the pentyl side chain 
(m/z 342, U19) was suggested by the fragment ions at m/z 144 and 230. Due to the close 
retention time with X16 (oxidative defluorination metabolite of XLR-11), U19 is likely to be 
hydroxylated at the 5-position of the pentyl side chain. Aldehyde at the TMCP ring followed 
by ketone at the pentyl side chain (m/z 340, U21) showed the fragment ions at the m/z 144 
and 228 representing ketone formation at the pentyl side chain. Carboxylation at the pentyl 
side chain with hydroxylation at the TMCP ring (m/z 358, U6, U8) was suggested by the ions 
at m/z 144 and 244 indicative of N-pentanoic acid, which was supported by the matching 
retention time with X1 and X4, respectively. Similarly, carboxylation at the TMCP ring with 
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hydroxylation at the pentyl side chain (m/z 358, U10, U12, U15) was indicated by the ions at 
m/z 144 and 230. U10 was considered to be the same metabolite as X8 and is expected to 
have been hydroxylated at the terminal carbon. 
Ketone formation at the pentyl side chain with hydroxylation at the TMCP ring (m/z 342, 
U14, U18) was suggested by the fragment ions at m/z 144 and 228. Ketone at the pentyl side 
chain with carboxylation at the TMCP ring (m/z 345, U17, U20) was represented by the 
fragment ions at m/z 144 and 228. 
 
Comparison of fungal metabolites with reported human metabolites 
For 5F-PB-22 and PB-22, the fungal metabolites were generally in good agreement with 
reported human in vitro metabolites (Tables 1 and 2). Almost all types of individual 
biotransformations reported for the human metabolism were observed for the fungal 
metabolism though not necessarily in the same combinations; the only transformations that 
lacked with the fungus were cysteine conjugation and glucuronidation. The important 
difference, however, was that ester hydrolysis that forms 5F-PI-COOH/PI-COOH was the 
main pathway found by human hepatocytes [17] and HLM [22] while it was not a major 
pathway for C. elegans. In hepatocytes, three out of the five most abundant 5F-PB-22 
metabolites are ester hydrolysis products with/without hydroxylation or glucuronidation 
whereas all seven major metabolites of PB-22 are ester hydrolysis products with/without 
hydroxylation, ketone formation and/or glucuronidation [17]. In contrast, all the fungal 
metabolites with ester hydrolysis were among the minor metabolites. However, it should be 
noted that metabolites generated by in vitro models like hepatocytes and HLM are not always 
consistent with human urinary metabolites. Accordingly, it would have been ideal to compare 
the fungal metabolites directly with human urinary metabolites, but unfortunately such data 
was unavailable.  
The majority of the human metabolites for XLR-11 and UR-144 were observed in the fungus 
samples (Tables 3 and 4). For XLR-11, hemiacetal, N-dealkylation, dehydration, hemiketal, 
trihydroxylation and glucuronidation were the only individual transformations found in both 
in vivo and in vitro human metabolism that were not generated by the fungus. The major 
human urine metabolites have been reported to be oxidative defluorination and oxidative 
defluorination to carboxylic acid with/without hydroxylation [45, 46], mostly of the pyrolysis 
product formed from thermal degradation due to smoking. All these metabolites were found 
in the fungus culture, though not of the pyrolysis product as the process of heating was not 
involved in this study, and metabolites with oxidative defluorination to carboxylic acid with 
hydroxylation (X1 and X4) were the fourth and fifth abundant fungal metabolites among 26 
metabolites indicating good correlation in abundance. With UR-144, although metabolites 
with aldehyde, carboxylation, ketone or N-dealkylation alone were absent, all the reported 
human biotransformations including the four aforementioned were detected in fungal 
metabolism. Hydroxylation and dihydroxylation are reported major human urine metabolites 
[6, 47] and two dihydroxylated metabolites (U7 and U11) were found to be the two most 
abundant fungal metabolites. 
These findings demonstrate that C. elegans is capable of most biotransformations observed 
for the four synthetic cannabinoids in humans, which is consistent with the previous studies 
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on JWH-018, JWH-073 and AM2201 [33]. Hence, it shows the potential to be used to predict 
metabolism of future cannabinoids, complementary to other models, and to characterise 
metabolites by NMR analysis. However, two distinct differences between the fungus and 
human metabolism seem to exist. One is that glucuronides were not observed in this study 
and instead glucosides were generated by the fungus. This finding agrees with the study on 
the synthetic cannabinoid AM2201 that glucosidation and sulfation are the only phase II 
reactions observed for C. elegans metabolism while glucuronidation is the major phase II 
transformation in humans [33]. Similarly, for some other drugs, glucosidation and sulfation 
are reported to be the phase II reactions of C. elegans while the same drugs are 
glucuronidated and sulfated in humans [38, 48]. The latter experiments did not involve 
extraction step as a sample preparation, supporting that poor recovery of glucuronides in 
dichloromethane is not likely a reason for the absence of glucuronides in this study. 
Furthermore, the retention time of the glucosides observed in this study were between 6-10 
min. If glucuronides of corresponding aglycones were present in the culture, they would 
likely have been extracted by dichloromethane, which did extract polar compounds derived 
from matrix eluting between 3-6 min. This indicates that phase II metabolites produced by 
the fungus, particularly glucosides, may be irrelevant and need to be interpreted with caution, 
if hydrolysis step is not included in sample preparation before urinalysis. The other difference 
is that ester hydrolysis was clearly not a favoured pathway in the fungal metabolism. 
Previously, incubation of steroidal drug, ethynodiol diacetate containing two ester groups, 
with C. elegans and Ocimum basilicum has been reported [49] and while ester hydrolysis did 
not occur with C. elegans, three of the four metabolites by Ocimum basilicum underwent 
hydrolysis suggesting that C. elegans may not favour ester hydrolysis in general. Some of the 
other discrepancy between the fungus and human metabolites may be due to dosages, 
possible co-administration of drugs in authentic human samples, incubation/sampling time. 
Finally, there are limitations of the comparison method. Each biotransformation observed for 
fungus and human metabolism was compared in this study. While this method provides 
useful information on the major metabolic pathways, specific isomers found in fungal 
metabolism may not always be the exact isomers found in human metabolism, e.g. 2-
pentylhydroxy isomer in fungus vs. 4-pentylhydroxy isomer in human urine. This limitation 
is inherent to the mass spectrometry technique used and highlights the need to use other 
complimentary techniques such as NMR to aid unambiguous structural elucidation of 
metabolites and to facilitate more accurate comparison. 
 
Comparison of fungal model with in vitro human models 
One of the incentives to use the fungus is the cost efficiency of the model. Unlike human 
hepatocytes or HLM, fungus can be repeatedly subcultured as required for new experiments. 
Therefore, once the stock culture of the fungus is obtained, potato dextrose agar plates for 
subculturing will essentially be the only cost associated for the subsequent use of fungus. 
Regarding extrapolation of metabolic profiles to human metabolism, human hepatocytes 
appear to best serve the purpose as the biotransformations observed are most closely aligned 
to human metabolites including the phase II metabolites as observed for XLR-11 (Table 3) 
and the metabolite abundance is often closer to in vivo human metabolites [8]. While C. 
elegans did not match the human metabolites for XLR-11 as well as hepatocytes, it seems 
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just as useful as HLM, generating most of the HLM metabolites in addition to those not 
produced by HLM (Tables 1-4). 
As previously mentioned, the fungus metabolism can be scaled up to produce amounts of 
metabolites sufficient for NMR analysis. This is useful because it allows for more definitive 
characterisation of metabolites. Metabolites/isomers found in human urine and in vitro 
studies are not always conclusively characterised since commercially available reference 
standards do not cover all the potential metabolites and isomers. With upscaling of fungus 
metabolism followed by NMR analysis, the obtained metabolites could act as reference 
standards and in conjunction with human metabolism studies, appropriate biomarkers can be 
suggested. The quantity of drugs and volume of the media required for upscaling will depend 
on how much drug is metabolised, how many metabolites are to be analysed, abundance of 
major metabolites among all the metabolites, recovery of the metabolites in extraction and 
sensitivity of NMR spectrometer. In this study, these parameters were not quantified, and 
consequently it is difficult to estimate the quantity and volume required. Previous studies 
report that as little as 0.9 mg of 18-nor-oxandrolone in 30 mL of media is sufficient for 
analysis of two metabolites [39] while five metabolites of adrenosterone were generated from 
450 mg in 3 L, indicating the variability of the quantity and volume from case to case. 
 
Conclusion 
Metabolism of four synthetic cannabinoids, 5F-PB-22, XLR-11 and their defluorinated 
analogues PB-22 and UR-144 respectively, were investigated using the fungus C. elegans. 
The phase I and II metabolites were identified based on LC-QTOF analysis and their 
metabolic pathways were proposed. Hydroxylation, dihydroxylation, dihydrodiol formation, 
oxidative defluorination, oxidative defluorination to carboxylic acid, ester hydrolysis, 
glucosidation and combinations of these were observed for 5F-PB-22 with some of them only 
appearing as combinations. For PB-22, transformations were similar, but trihydroxylation, 
ketone formation and carboxylation were found instead of oxidative defluorination (to 
carboxylic acid). XLR-11 underwent hydroxylation, dihydroxylation, aldehyde formation, 
carboxylation, oxidative defluorination, oxidative defluorination to carboxylic acid and 
glucosidation either alone or in combinations. With UR-144, trihydroxylation, ketone 
formation and N-dealkylation were observed instead of oxidative defluorination (to 
carboxylic acid) and glucosidation. Comparison of the fungal metabolites with reported 
human metabolites showed that while C. elegans has limitations, such as low abundance of 
ester hydrolysis and absence of glucuronidation, overall the metabolic profiles were in good 
agreement. Therefore, it might have the potential to be a complementary model for synthetic 
cannabinoid metabolism. 
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Fig. 1. MS/MS spectra obtained with CE 20 eV and structures with the suggested 
fragmentation patterns and their exact masses for the parent drugs (5F-PB-22, PB-22, XLR-
11 and UR-144) and their most abundant fungal metabolites based on peak area (F10, P13, 
X21 and U7). The exact position of the dihydrodiol structure within quinolone moiety in F10 





























































































































Fig. 2. Combined extracted ion chromatograms of all metabolites and their respective parent 











































































































































































Fig. 3. Proposed metabolic pathway of 5F-PB-22 by C. elegans. Blue colour denotes a Phase 
II metabolite. Parenthesis represents a possible intermediate metabolite that was not detected 
in the study. For the metabolites with dihydrodiol structure, only one possible isomer is 





















































































Fig. 4. Proposed metabolic pathway of PB-22 by C. elegans. Blue colour denotes Phase II 
metabolites. Parentheses represent possible intermediate metabolites that were not detected in 
the study. For the metabolites with dihydrodiol structure, only one possible isomer is shown 



































































































































































































































































































Table I. Comparison of 5F-PB-22 metabolites formed by fungus, Cunninghamella elegans, 
with those by human hepatocytes and human liver microsomes reported in literature. 
Metabolites CE HHep HLM 
5F-PI-COOH [F12] √ √ [17] √ [22] 
5F-PI-COOH + glucosidation [F2] √   
5F-PI-COOH + glucuronidation  √ [17]  
5F-PI-COOH + cysteine conjugation  √ [17]  
5F-PI-COOH + hydroxylation [F4] √ √ [17]  
5F-PI-COOH + hydroxylation + glucuronidation  √ [17]  
5F-PI-COOH + oxidative defluorination  √ [17]  
5F-PI-COOH + oxidative defluorination to carboxylic acid  √ [17]  
5F-PI-COOH + oxidative defluorination to carboxylic acid + 
glucuronidation 
 √ [17]  
Dihydrodiol formation [F10] √ √ [17]  
Dihydrodiol formation + hydroxylation [F3] √   
Dihydroxylation [F7-F9] √   
Dihydroxylation + glucuronidation  √ [17]  
Hydroxylation [F14 - F16] √ √ [17]  
Hydroxylation + glucuronidation  √ [17]  
Oxidative defluorination + dihydrodiol formation [F1] √   
Oxidative defluorination + glucuronidation  √ [17]  
Oxidative defluorination to carboxylic acid [F13] √ √ [17]  
Oxidative defluorination to carboxylic acid + glucuronidation  √ [17]  
Oxidative defluorination to carboxylic acid + hydroxylation 
[F5, F6, F11] 
√   
CE Cunninghamella elegans; HHep Human hepatocytes; HLM Human liver microsomes 
Square brackets in Metabolites column indicate the ID of corresponding fungal metabolites. 












Table II. Comparison of PB-22 metabolites formed by fungus, Cunninghamella elegans, with 
those by human hepatocytes and human liver microsomes reported in literature. 
Metabolites CE HHep HLM 
Carboxylation [P24] √ √ [17]  
Carboxylation + hydroxylation [P12] √   
Dihydrodiol formation [P27] √ √ [17]  
Dihydrodiol formation + hydroxylation [P3, P7] √   
Dihydrodiol formation + ketone formation [P8, P14] √   
Dihydroxylation [P13, P15, P16, P19] √   
Hydroxylation [P26, P28] √ √ [17]  
Hydroxylation + glucuronidation  √ [17]  
Ketone formation [P29, P30] √ √ [17]  
Ketone formation + dihydroxylation [P4, P5, P9, P18] √   
Ketone formation + hydroxylation [P17, P20 - P23, P25] √   
Ketone formation + hydroxylation + glucosidation [P1] √   
PI-COOH  √ [17] √ [22] 
PI-COOH + glucosidation [P10] √   
PI-COOH + glucuronidation  √ [17]  
PI-COOH + carboxylation + glucuronidation  √ [17]  
PI-COOH + cysteine conjugation  √ [17]  
PI-COOH + hydroxylation [P6, P11] √ √ [17]  
PI-COOH + hydroxylation + glucuronidation  √ [17]  
PI-COOH + ketone formation + glucuronidation  √ [17]  
Trihydroxylation [P2] √   
CE Cunninghamella elegans; HHep Human hepatocytes; HLM Human liver microsomes 
Square brackets in Metabolites column indicate the ID of corresponding fungal metabolites. 














Table III. Comparison of XLR-11 metabolites formed by fungus, Cunninghamella elegans, 
with those in human urine and human liver microsomes reported in literature. 
Metabolites CE HU HH HHep HLM HRG 
XLR-11  Pyrolysis 
producta 
XLR-11  Pyrolysis 
producta 
Aldehyde formationb [X26] √    √ [16] √ [50]   
Aldehyde formation + 
hydroxylation followed by 
hemiacetal formation + 
glucuronidation 
    √ [16]    
Carboxylation [X22] √    √ [16] √ [50]   
Carboxylation + glucosidation 
[X14, X18] 
√        
Carboxylation + glucuronidation     √ [16]    
Carboxylation + hydroxylation 
[X10] 
√    √ [16]    
Dihydroxylation [X3, X6, X9, 
X11-X13, X19, X20] 
√  √ [45]    √ [45] √ [45] 
Dihydroxylation + 
glucuronidation 
 √ [46] √ [46]  √ [16]    
Hydroxylation [X21, X23] √ √ [51] √ [45, 46] √ [52]  √ [50] √ [45] √ [45] 
Hydroxylation + glucuronidation     √ [16]    
N-dealkylation      √ [50]   
Oxidative defluorination [X25] √ √ [45, 
46] 
√ [45] √ [52] √ [16] √ [46, 
50] 
√ [45] √ [45] 
Oxidative defluorination + 
glucuronidation 
 √ [46] √ [46]  √ [16]    
Oxidative defluorination + 
aldehyde formationb [X16] 
√     √ [50]   
Oxidative defluorination + 
carboxylation [X8] 
√    √ [16] √ [50]   
Oxidative defluorination + 
hydroxylation [X2, X7] 
√  √ [45]   √ [50] √ [45] √ [45] 
Oxidative defluorination + 
hydroxylation + glucuronidation 
  √ [46]  √ [16]    
Oxidative defluorination to 
carboxylic acid [X24] 
√ √ [45, 
46] 
√ [45, 46] √ [52] √ [16] √ [46] √ [45] √ [45] 
Oxidative defluorination to 
carboxylic acid + 
glucuronidation 
  √ [46]  √ [16]    
Oxidative defluorination to 
carboxylic acid + aldehyde 
formationb [X15, X17] 
√    √ [16]    
Oxidative defluorination to 
carboxylic acid + aldehyde 
formation + hydroxylation 
followed by hemiacetal 
formation 
    √ [16]    
Oxidative defluorination to 
carboxylic acid + aldehyde 
formation + hydroxylation 
followed by hemiacetal 
formation + glucuronidation 
    √ [16]    
Oxidative defluorination to √ √ [46] √ [46]  √ [16]    
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carboxylic acid + carboxylation 
[X5] 
Oxidative defluorination to 
carboxylic acid + carboxylation 
+ glucuronidation 
    √ [16]    
Oxidative defluorination to 
carboxylic acid + hydroxylation 
[X1, X4] 
√ √ [46] √ [45, 46]  √ [16]  √ [45] √ [45] 
Oxidative defluorination to 
carboxylic acid + hydroxylation 
+ dehydration 
 √ [46] √ [46]      
Oxidative defluorination to 
carboxylic acid + hydroxylation 
+ hemiketal formation 
    √ [16]    
Trihydroxylation + 
glucuronidation 
    √ [16]    
CE Cunninghamella elegans; HU Human urine; HH Human hair; HHep Human hepatocytes; 
HLM Human liver microsomes; HRG HepaRG cells 
a Metabolites of XLR-11 pyrolysis product are shown separately from those of non-pyrolysed 
XLR-11. 
b The biotransformation proposed as ‘dioxidation followed by internal dehydration’ in the 
reference is included since it might be the same biotransformation. 
Square brackets in Metabolites column indicate the ID of corresponding fungal metabolites. 

















Table IV. Comparison of UR-144 metabolites formed by fungus, Cunninghamella elegans, 
with those in human urine and human liver microsomes reported in literature. 
Metabolites CE HU HLM 
UR-144  Pyrolysis 
producta 
Aldehyde formationb     √ [6, 50] 
Aldehyde formationb + hydroxylation [U19] √   √ [50] 
Aldehyde formation + ketone formation [U21] √    
Carboxylation  √ [51] √ [47, 51, 53] √ [50] 
Carboxylation + hydroxylation [U6, U8, U10, U12, 
U15] 
√   √ [50] 
Dihydroxylation [U7, U11, U13, U16] 
√ √ [6, 47, 
53] 
√ [47, 53] √ [6, 50] 
Hydroxylation [U22 – U25] 
√ √ [6, 47, 
51] 
√ [47, 53] √ [6, 50] 
Ketone formation    √ [6] 
Ketone formation + carboxylation [U17, U20] √    
Ketone formation + hydroxylation [U14, U18] √ √ [47] √ [47]  
N-dealkylation  √ [6]  √ [6] 
N-dealkylation + hydroxylation [U4, U9] √ √ [47] √ [47] √ [6] 
Trihydroxylation [U1 - U3, U5]  √    
CE Cunninghamella elegans; HU Human urine; HLM Human liver microsomes 
a Metabolites of UR-144 pyrolysis product are shown separately from those of non-pyrolysed 
UR-144. 
b The biotransformation proposed as ‘dioxidation followed by internal dehydration’ or 
‘dehydrated hydroxy’ in the reference is included since they might be the same 
biotransformation. 
Square brackets in Metabolites column indicate the ID of corresponding fungal metabolites.
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Supplementary Table I 
5F-PB-22 metabolites with retention time, elemental composition, exact mass, accurate mass, mass error and diagnostic product ions. 
 












F1 Oxidative deluorination + dihydrodiol formation 6.4 C23H25N2O5 409.1758 409.1761 0.76 230 
F2 5F-PI-COOH + glucosidation 6.6 C20H27FNO7 412.1766 412.1772 1.39 118, 132, 144, 206, 
232, 250 
F3 Dihydrodiol formation + hydroxylation 6.7 C23H24FN2O5 427.1664 427.1665 0.35 248 
F4 5F-PI-COOH + hydroxylation 7.4 C14H17FNO3 266.1187 266.1191 1.12 134, 148, 174, 222, 
248 
F5 Oxidative defluorination to carboxylic acid + 
hydroxylation 
7.7 C23H21N2O5 405.1445 405.1448 0.71 144, 244 
F6 Oxidative defluorination to carboxylic acid + 
hydroxylation 
7.9 C23H21N2O5 405.1445 405.1447 0.53 160, 260 
F7 Dihydroxylation 7.9 C23H22FN2O4 409.1558 409.1560 0.52 144, 248 
F8 Dihydroxylation 8.2 C23H22FN2O4 409.1558 409.1557 -0.36 144, 158, 248 
F9 Dihydroxylation 8.7 C23H22FN2O4 409.1558 409.1561 0.77 264 
F10 Dihydrodiol formation 9.4 C23H24FN2O4 411.1715 411.1715 0.09 144, 232 
F11 Oxidative defluorination to carboxylic acid + 
hydroxylation 
9.6 C23H21N2O5 405.1445 405.1449 0.91 144, 244 




F13 Oxidative defluorination to carboxylic acid 11.1 C23H21N2O4 389.1496 389.1498 0.54 144, 244 
F14 Hydroxylation 11.6 C23H22FN2O3 393.1609 393.1612 0.75 144, 248 
F15 Hydroxylation 12.1 C23H22FN2O3 393.1609 393.1612 0.72 144, 158, 248 
F16 Hydroxylation 12.6 C23H22FN2O3 393.1609 393.1610 0.32 144, 248 



















Supplementary Table II 
PB-22 metabolites with retention time, elemental composition, exact mass, accurate mass, mass error and diagnostic product ions. 
 









Diagnostic product ions 
P1 Ketone formation + hydroxylation + 
glucosidation 
6.2 C29H31N2O9 551.2024 551.2028 0.69 160, 244 
P2 Trihydroxylation 6.4 C23H23N2O5 407.1601 407.1599 -0.56 144, 246 
P3 Dihydrodiol formation + hydroxylation 6.5 C23H25N2O5 409.1758 409.1763 1.13 144, 230 
P4 Ketone formation + dihydroxylation 6.5 C23H21N2O5 405.1445 405.1449 0.97 160, 244 
P5 Ketone formation + dihydroxylation 6.9 C23H21N2O5 405.1445 405.1449 1.08 144, 244 
P6 PI-COOH + hydroxlyation 6.9 C14H18NO3 248.1281 248.1284 1.26 130, 144, 158, 174, 230 
P7 Dihydrodiol formation + hydroxylation 7.0 C23H25N2O5 409.1758 409.1748 -2.51 144, 158 (230 is missing in 
QTOF but present in QqQ) 
P8 Dihydrodiol formation + ketone formation 7.0 C23H23N2O5 407.1601 407.1603 0.36 144, 228 
P9 Ketone formation + dihydroxylation 7.4 C23H21N2O5 405.1445 405.1448 0.62 244 (144 is missing in QTOF 
but present in QqQ) 
P10 PI-COOH + glucosidation 7.5 C14H18NO2 394.1860 394.1858 -0.55 118, 130, 132, 144, 158, 186, 
214, 232 
P11 PI-COOH + hydroxlyation 7.6 C14H18NO3 248.1281 248.1283 0.92 130, 174, 230 
P12 Carboxylation + hydroxylation 7.7 C23H21N2O5 405.1445 405.1443 -0.51 144, 244 
P13 Dihydroxylation 7.8 C23H23N2O4 391.1652 391.1654 0.41 144, 230 
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P14 Dihydrodiol formation + ketone formation 7.8 C23H23N2O5 407.1601 407.1604 0.58 144, 228 
P15 Dihydroxylation 8.0 C23H23N2O4 391.1652 391.1655 0.58 144, 246 
P16 Dihydroxylation 8.5 C23H23N2O4 391.1652 391.1653 0.27 144, 246 
P17 Ketone formation + hydroxylation 8.5 C23H21N2O4 389.1496 389.1500 1.1 144, 228 
P18 Ketone formation + dihydroxylation 8.6 C23H21N2O5 405.1445 405.1444 -0.17 260 (144 is missing in QTOF 
but present in QqQ) 
P19 Dihydroxylation 8.7 C23H23N2O4 391.1652 391.1654 0.41 144, 246 
P20 Ketone formation + hydroxylation 8.9 C23H21N2O4 389.1496 389.1498 0.55 144, 228 
P21 Ketone formation + hydroxylation 9.8 C23H21N2O4 389.1496 389.1498 0.56 144, 244 
P22 Ketone formation + hydroxylation 10.1 C23H21N2O4 389.1496 389.1493 -0.78 144, 228 
P23 Ketone formation + hydroxylation 10.8 C23H21N2O4 389.1496 389.1494 -0.35 144, 244 
P24 Carboxylation 11.1 C23H21N2O4 389.1496 389.1493 -0.84 144, 244 
P25 Ketone formation + hydroxylation 11.3 C23H21N2O4 389.1496 389.1500 1.1 144, 228 
P26 Hydroxylation 11.5 C23H23N2O3 375.1703 375.1706 0.66 144, 230 
P27 Dihydrodiol formation 12.0 C23H25N2O4 393.1809 393.1812 0.72 144, 214 
P28 Hydroxylation 13.2 C23H23N2O3 375.1703 375.1695 -2.06 130, 144, 158, 230 
P29 Ketone formation 13.4 C23H21N2O3 373.1547 373.1547 0.11 144, 228 
P30 Ketone formation 15.1 C23H21N2O3 373.1547 373.1547 0.06 144, 228 






Supplementary Table III 
XLR-11 metabolites with retention time, elemental composition, exact mass, accurate mass, mass error and diagnostic product ions. 
 










X1 Oxidative defluorination to carboxylic acid + 
hydroxylation 
7.5 C21H28NO4 358.2013 358.2012 -0.27 144, 244 
X2 Oxidative defluorination + hydroxylation 7.7 C21H30NO3 344.2220 344.2203 -5.1 144, 230 
X3 Dihydroxylation 7.8 C21H29FNO3 362.2126 362.2121 -1.49 144, 248 
X4 Oxidative defluorination to carboxylic acid + 
hydroxylation 
7.8 C21H28NO4 358.2013 358.2011 -0.38 144, 244 
X5 Oxidative defluorinaton to carboxylic acid + 
carboxylation 
7.9 C21H26NO5 372.1805 372.1807 0.35 144, 244, 354 
X6 Dihydroxylation 8.0 C21H29FNO3 362.2126 362.2126 -0.13 144, 232 
X7 Oxidative defluorination + hydroxylation 8.1 C21H30NO3 344.2220 344.2207 -3.79 144, 230 
X8 Oxidative defluorination + carboxylation 8.1 C21H28NO4 358.2013 358.2008 -1.3 144, 230 
X9 Dihydroxylation 8.1 C21H29FNO3 362.2126 362.2122 -1.22 144, 248 
X10 Carboxylation + hydroxylation 8.4 C21H27FNO4 376.1919 376.1915 -1.01 130, 144, 248, 358 
X11 Dihydroxylation 8.4 C21H29FNO3 362.2126 362.2123 -0.83 144, 248 
X12 Dihydroxylation 8.5 C21H29FNO3 362.2126 362.2125 -0.19 144, 232 
X13 Dihydroxylation 8.8 C21H29FNO3 362.2126 362.2124 -0.49 144, 232 
X14 Carboxylation + glucosidation (in-source 
fragmentation) 
8.9 C21H27FNO3 360.1969 360.1966 -0.99 144, 232, 342 
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X15 Oxidative defluorination to carboxylic acid + 
aldehyde formation 
9.0 C21H26NO4 356.1856 356.1854 -0.7 144, 244 
X16 Oxidative defluorination + aldehyde 
formation 
9.4 C21H28NO3 342.2064 342.2061 -0.67 144, 230 
X17 Oxidative defluorination to carboxylic acid + 
aldehyde formation 
9.6 C21H26NO4 356.1856 356.1851 -1.55 144, 244 
X18 Carboxylation + glucosidation (in-source 
fragmentation) 
9.8 C21H27FNO3 360.1969 360.1965 -1.25 144, 232, 342 
X19 Dihydroxylation 10.7 C21H29FNO3 362.2126 362.2124 -0.48 144, 232 
X20 Dihydroxylation 11.0 C21H29FNO3 362.2126 362.2122 -0.98 144, 232 
X21 Hydroxylation 11.6 C21H29FNO2 346.2177 346.2176 -0.28 144, 232 
X22 Carboxylation 12.3 C21H27FNO3 360.1969 360.1967 -0.6 144, 232, 342 
X23 Hydroxylation 12.8 C21H29FNO2 346.2177 346.2173 -1.01 144, 232 
X24 Oxidative defluorination to carboxylic acid 13.3 C21H28NO3 342.2064 342.2059 -1.29 125, 144, 244 
X25 Oxidative defluorination 14.2 C21H30NO2 328.2271 328.2265 -1.89 125, 144, 230 
X26 Aldehyde formation 14.6 C21H27FNO2 344.2020 344.2017 -0.86 144, 232 









Supplementary Table IV 
UR-144 metabolites with retention time, elemental composition, exact mass, accurate mass, mass error and diagnostic product ions. 
 










U1 Trihydroxylation 6.2 C21H30NO4 360.2169 360.2165 -1.11 144, 230 
U2 Trihydroxylation 6.5 C21H30NO4 360.2169 360.2166 -0.82 144, 230 
U3 Trihydroxylation 7.3 C21H30NO4 360.2169 360.2165 -1.27 144, 230 
U4 N-dealkylation + hydroxylation 7.5 C16H20NO2 258.1489 258.1487 -0.68 116, 144 
U5 Trihydroxylation 7.6 C21H30NO4 360.2169 360.2163 -1.73 144, 230 
U6 Carboxylation + hydroxylation 7.6 C21H28NO4 358.2013 358.2009 -1.15 144, 244 
U7 Dihydroxylation 7.8 C21H30NO3 344.2220 344.2215 -1.6 144, 230 
U8 Carboxylation + hydroxylation 7.9 C21H28NO4 358.2013 358.2009 -1.16 144, 244 
U9 N-dealkylation + hydroxylation 7.9 C16H20NO2 258.1489 258.1490 0.43 116, 144 
U10 Carboxylation + hydroxylation 8.2 C21H28NO4 358.2013 358.2007 -1.76 144, 230, 340 
U11 Dihydroxylation 8.3 C21H30NO3 344.2220 344.2216 -1.25 144, 230 
U12 Carboxylation + hydroxylation 8.5 C21H28NO4 358.2013 358.2014 0.28 144, 230, 340 
U13 Dihydroxylation 8.6 C21H30NO3 344.2220 344.2218 -0.51 144, 230 
U14 Ketone formation + hydroxylation 8.8 C21H28NO3 342.2064 342.2061 -0.78 144, 228 




U16 Dihydroxylation 9.2 C21H30NO3 344.2220 344.2217 -0.95 144, 230 
U17 Ketone formation + carboxylation 9.3 C21H26NO4 356.1856 356.1855 -0.24 144, 228, 338 
U18 Ketone formation + hydroxylation 9.5 C21H28NO3 342.2064 342.2061 -0.76 144, 228 
U19 Aldehyde formation + hydroxylation 9.6 C21H28NO3 342.2064 342.2059 -1.25 144, 230 
U20 Ketone formation + carboxylation 10.3 C21H26NO4 356.1856 356.1854 -0.61 130, 144, 228, 338 
U21 Aldehyde formation + ketone formation 11.1 C21H26NO3 340.1907 340.1910 0.82 144, 228 
U22 Hydroxylation 14.4 C21H30NO2 328.2271 328.2264 -2.04 125, 144, 230 
U23 Hydroxylation 14.7 C21H30NO2 328.2271 328.2268 -0.79 125, 144, 230 
U24 Hydroxylation 15.3 C21H30NO2 328.2271 328.2268 -1.02 144, 214 
U25 Hydroxylation 17.4 C21H30NO2 328.2271 328.2266 -1.5 144, 214 
Parent UR-144 26.1 C21H30NO 312.2322 312.2320 -0.72 125, 144, 214 
 
